A prospective study reveals that individuals with inflammatory bowel disease (IBD), ulcerative colitis, and Crohn disease have a significantly higher risk of developing chronic obstructive pulmonary disease...
Two phase 3 randomized trials evaluated the efficacy of risankizumab in patients with moderately to severely active ulcerative colitis. The results show significantly higher remission rates with...
Two phase 3 randomized trials evaluated the efficacy of risankizumab in patients with moderately to severely active ulcerative colitis. The results show significantly higher remission rates with...
Researchers compared the health outcomes of adult patients with moderate ulcerative colitis and early advanced therapy initiation with those who delayed their advanced treatment initiation.
Researchers compared the health outcomes of adult patients with moderate ulcerative colitis and early advanced therapy initiation with those who delayed their advanced treatment initiation.
The American Gastroenterological Association (AGA) released a set of guidelines that outlines the use of biomarkers to treat and monitor ulcerative colitis in patients.
The researchers sought to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with moderate-to-severe ulcerative colitis.
The researchers sought to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with moderate-to-severe ulcerative colitis.
Researchers conducted a systematic review and meta-analysis to evaluate the efficacy and safety of fecal microbiota transplantation as a treatment for ulcerative colitis.
